Science AI Journal
Biochemistry, Genetics and Molecular Biology · Research topic

Open research questions in Chromatin Remodeling and Cancer

85 unresolved questions extracted from the limitations and future-work sections of 201 Chromatin Remodeling and Cancer papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • the molecular mechanisms underlying the drug resistance phenotype remain incompletely characterized, - complementary loss-of-function experiments are still required, - the actual number of patients diagnosed clinically is significantly higher than the reported data

    Decitabine modulates dopamine agonist sensitivity in gh3 rat pituitary tumor cells via Trim7 · 2026 · DOI

  • finding new treatment methods through drug means, - improving the sensitivity of DARPs to DAs, - investigating the cause of characteristic changes in DARPs

    Decitabine modulates dopamine agonist sensitivity in gh3 rat pituitary tumor cells via Trim7 · 2026 · DOI

  • further evaluation of ARID1A as a potential biomarker of therapeutic response, - exploration of the molecular changes linked to CCC, - investigation of the functions of variant genes

    ARID1A deficiency identifies molecular alterations and potential therapeutic implications in cervical clear cell carcinoma: an integrated genomic and clinicopathological study · 2026 · DOI

  • Background Cervical clear cell carcinoma (CCC) is a rare and aggressive subtype of cervical adenocarcinoma whose molecular drivers and therapeutic vulnerabilities remain incompletely defined.

    ARID1A deficiency identifies molecular alterations and potential therapeutic implications in cervical clear cell carcinoma: an integrated genomic and clinicopathological study · 2026 · DOI

  • Reliable models that represent this disease and can be used for translational research are scarce.

    Organoid drug profiling identifies methotrexate as a therapy for SCCOHT, a rare pediatric cancer · 2025 · DOI

  • The vascular niche is crucial for maintaining cardiac homeostasis, yet endothelial cell (EC) impairment during aging remains poorly understood.

    Endothelial ZBTB16: a molecular shield against cardiac aging · 2025 · DOI

  • Further investigation into genetic and socioeconomic factors contributing to these observed inequities is needed.

    Genetic ancestry superpopulations show distinct prevalence and outcomes across pediatric central nervous system tumors from the Pediatric Brain Tumor Atlas and Pediatric Neuro-Oncology Consortium · 2025 · DOI

  • SMARCB1-deficient cancers are defined by loss of cell differentiation-associated enhancers, but how SWI/SNF interacts with other arbiters of cell differentiation (specifically lineage-specific transcription factors [TFs]) remains poorly understood.

    SWI/SNF complexes govern ontology-specific transcription factor function in MYC-subtype atypical teratoid rhabdoid tumor · 2025 · DOI

  • The predictive value of ARID1A for predicting ICI effectiveness has not been reported for endometrial cancer.

    Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial Cancer · 2024 · DOI

  • CONCLUSION: The primary features of DS involve severe insulin resistance and growth abnormalities, the association with pulmonary hypertension (PHTN) has not been reported before.

    “An unprecedented occurrence: a case report of pulmonary hypertension manifestation in Donohue syndrome” · 2024 · DOI

  • However, the specific roles of class VII variants in tissue homeostasis and repair have not yet been determined.

    Discovery of NRG1-VII: the myeloid-derived class of NRG1 · 2024 · DOI

  • Although recent studies have uncovered 3 molecular subgroups of ATRTs with distinct disease patterns, and signaling features, the therapeutic profiles of ATRT subgroups remain incompletely elucidated.

    A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors · 2024 · DOI

  • Further studies are needed to investigate the molecular features of synchronous gynecologic tumors. The use of immunohistochemical staining to examine p53 and BRG1 expression in synchronous tumors should be further explored. The development of diagnostic criteria for distinguishing between independent primary tumors and metastatic disease in synchronous gynecologic tumors is necessary.

    Discordant p53 and BRG1 expression in synchronous low-grade uterine endometrioid carcinoma and SMARCA4-deficient ovarian undifferentiated carcinoma: a case report · 2026 · DOI

  • The diagnosis of synchronous gynecologic tumors requires careful distinction between independent primary tumors and metastatic spread. There is a need for integrated clinicopathologic and molecular profiling to accurately diagnose and treat synchronous gynecologic tumors.

    Discordant p53 and BRG1 expression in synchronous low-grade uterine endometrioid carcinoma and SMARCA4-deficient ovarian undifferentiated carcinoma: a case report · 2026 · DOI

  • The rarity of spAT/RT limits the understanding of prognostic factors and optimal treatment regimens, - Delayed referral pathways, limited availability of advanced neuroimaging, and restricted access to specialized pediatric oncology and neurosurgical centers compromise effective management, - Many LMIC centers lack access to diagnostic modalities, - The study is a review of published literature and may not reflect the current state of knowledge

    Pediatric Spinal Atypical Teratoid Rhabdoid Tumor: Recent Advances in Biology and Management Options · 2026 · DOI

  • Further studies are needed to understand the biology of spAT/RT and to develop effective treatment strategies, - Research on the molecular characteristics of spAT/RT may lead to the development of targeted therapies, - Investigations into the optimal treatment regimens for spAT/RT are necessary, - Studies on the management of spAT/RT in low-and middle-income countries are required

    Pediatric Spinal Atypical Teratoid Rhabdoid Tumor: Recent Advances in Biology and Management Options · 2026 · DOI

  • The disease has nonspecific imaging features, making diagnosis challenging. The disease is characterized by rapid clinical progression and poor prognosis. There is a need to improve diagnosis and treatment of this disease.

    CT imaging features of pulmonary SMARCA4-deficient undifferentiated carcinoma: a retrospective case series · 2026 · DOI

  • The aggressive nature of SMARCA4-deficient undifferentiated cervical tumors. The limited treatment options available for these tumors. The potential side effects and toxicity of the treatment approach used.

    PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report · 2026 · DOI

  • The lack of effective treatment options for massive SMARCA4-deficient cervical tumors. The need for novel treatment approaches that can improve patient outcomes and quality of life.

    PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report · 2026 · DOI

  • The rarity of SWI/SNF complex-deficient tumors in the oral cavity. The lack of comprehensive molecular characterization of such tumors. The need for timely biopsy and thorough pathologic workup for peri-implant gingival masses.

    Peri-Implant Gingival Undifferentiated SWI/SNF Complex-Deficient Tumor with Molecularly Confirmed Biallelic SMARCA4 Inactivation: Diagnostic Pitfalls and Genomic Characterization · 2026 · DOI

  • The therapeutic window and risk of on-target toxicity of BUB1 inhibition remain uncertain. All available BUB1-targeting strategies remain preclinical, and no inhibitor has yet entered clinical testing. The evidence base for BUB1's role in certain tumor types remains uneven.

    BUB1 in cancer genetics and oncogenomics: from chromosomal instability to therapeutic vulnerabilities · 2026 · DOI

  • Further studies are needed to fully understand the role of BUB1 in cancer and its potential as a therapeutic target. Research is needed to develop BUB1-targeting strategies and to investigate their therapeutic potential. The distinction between kinase-dependent and scaffold-dependent functions of BUB1 needs to be resolved.

    BUB1 in cancer genetics and oncogenomics: from chromosomal instability to therapeutic vulnerabilities · 2026 · DOI

  • Herein, we aimed to investigate whether PNS-associated BCs display additional specificities, including stromal and vascular features that have not been systematically assessed.

    Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome · 2026 · DOI

  • Further investigation of the RAB3B-centric ceRNA network. Validation of the identified miRNAs as potential therapeutic targets for LUAD.

    Integrative genomic and functional analysis of RAB3B in lung adenocarcinoma: associations with m6A modification and ceRNA networks · 2026 · DOI

  • The lack of effective biomarkers and therapeutic targets for LUAD. The need to understand the regulatory mechanisms of RAB3B in LUAD.

    Integrative genomic and functional analysis of RAB3B in lung adenocarcinoma: associations with m6A modification and ceRNA networks · 2026 · DOI

Most-cited papers in Chromatin Remodeling and Cancer

Most recent work

Find a gap in your own Chromatin Remodeling and Cancer sub-topic

This page shows what the Chromatin Remodeling and Cancer literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 4.5M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Biochemistry, Genetics and Molecular Biology

Gut microbiota and health
1,988 open questions
Single-cell and spatial transcriptomics
739 open questions
Extracellular vesicles in disease
551 open questions
Antibiotic Resistance in Bacteria
540 open questions
Genetic Associations and Epidemiology
535 open questions
Inflammatory Bowel Disease
499 open questions
RNA modifications and cancer
423 open questions
Mitochondrial Function and Pathology
419 open questions
85 open questions have been extracted from the limitations and future-work passages of 201 Chromatin Remodeling and Cancer papers in our 4.5M-paper local library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.